Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Advertisement Advertisement Eric Van Cutsem (eric.vancutsem{at}uzleuven.be)*,a, Erika Martinellib, Stefano Cascinuc, Alberto Sobrerod, Maria Banzie, Jean‐François Seitzf, Carlo Baroneg, Marc Ychouh, Marc Peetersi, Baruch Brennerj,k, Ralf Dieter Hofheinzl, Evaristo Maiellom, Thierry Andrén, Andrea Spallanzanio, Rocio Garcia‐Carbonerop, Yull E.
Disclosures of potential conflicts of interest may be found at the end of this article. In the phase III CORRECT trial, regorafenib significantly improved survival in treatment‐refractory metastatic colorectal cancer (mCRC). The CONSIGN study was designed to further characterize regorafenib safety and allow patients access to regorafenib before market authorization. This prospective, single‐arm study enrolled patients in 25 countries at 186 sites.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
